PL2114405T3 - Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem - Google Patents
Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenemInfo
- Publication number
- PL2114405T3 PL2114405T3 PL07857734T PL07857734T PL2114405T3 PL 2114405 T3 PL2114405 T3 PL 2114405T3 PL 07857734 T PL07857734 T PL 07857734T PL 07857734 T PL07857734 T PL 07857734T PL 2114405 T3 PL2114405 T3 PL 2114405T3
- Authority
- PL
- Poland
- Prior art keywords
- methanone
- piperazin
- methanesulfonyl
- trifluoro
- pyridin
- Prior art date
Links
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 title 2
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 title 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 title 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 title 1
- 229960002216 methylparaben Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 | ||
| PCT/EP2007/064104 WO2008080821A1 (en) | 2006-12-28 | 2007-12-18 | Crystalline forms glyt1 |
| EP07857734.3A EP2114405B1 (en) | 2006-12-28 | 2007-12-18 | methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2114405T3 true PL2114405T3 (pl) | 2015-08-31 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07857734T PL2114405T3 (pl) | 2006-12-28 | 2007-12-18 | Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (https=) |
| EP (1) | EP2114405B1 (https=) |
| JP (1) | JP4799666B2 (https=) |
| KR (1) | KR101130146B1 (https=) |
| CN (1) | CN101573114A (https=) |
| AR (1) | AR064545A1 (https=) |
| AU (1) | AU2007341356B2 (https=) |
| BR (1) | BRPI0720829B8 (https=) |
| CA (1) | CA2673667A1 (https=) |
| CL (1) | CL2007003830A1 (https=) |
| CO (1) | CO6190613A2 (https=) |
| CR (1) | CR10846A (https=) |
| CY (1) | CY1116350T1 (https=) |
| DK (1) | DK2114405T3 (https=) |
| EC (1) | ECSP099471A (https=) |
| ES (1) | ES2535040T3 (https=) |
| HR (1) | HRP20150573T1 (https=) |
| HU (1) | HUE025032T2 (https=) |
| MA (1) | MA31029B1 (https=) |
| MX (1) | MX2009006859A (https=) |
| MY (1) | MY188367A (https=) |
| NO (1) | NO342150B1 (https=) |
| NZ (1) | NZ577502A (https=) |
| PE (1) | PE20081556A1 (https=) |
| PL (1) | PL2114405T3 (https=) |
| PT (1) | PT2114405E (https=) |
| RS (1) | RS53910B1 (https=) |
| RU (1) | RU2463295C2 (https=) |
| SI (1) | SI2114405T1 (https=) |
| TW (1) | TWI388552B (https=) |
| UA (1) | UA100232C2 (https=) |
| WO (1) | WO2008080821A1 (https=) |
| ZA (1) | ZA200904423B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
| JP6074142B2 (ja) * | 2009-02-26 | 2017-02-01 | タール ファーマシューティカルズ，インコーポレイテッド | 医薬化合物の結晶化 |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| CN104334550A (zh) * | 2012-05-25 | 2015-02-04 | 巴斯夫欧洲公司 | 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| JP7096956B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| EP4337199A4 (en) * | 2021-05-14 | 2025-03-19 | Disc Medicine, Inc. | Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents |
| CN118043050A (zh) * | 2021-05-27 | 2024-05-14 | 迪斯克医药公司 | 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| MX2009006859A (es) | 2006-12-28 | 2009-07-03 | Hoffmann La Roche | Formas cristalinas de glyt1. |
-
2007
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2114405T3 (pl) | Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem | |
| IL238068A0 (en) | New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine | |
| BRPI0716880A2 (pt) | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas | |
| IL195511A0 (en) | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] | |
| ZA200804198B (en) | Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides | |
| ZA201105992B (en) | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | |
| IL191729A0 (en) | Assessment of electrode coupling for tissue ablation | |
| WO2009043747A3 (en) | N-heterocyclic biaryl carboxamides as ccr receptor antagonists | |
| WO2008123469A1 (ja) | ６員環アミド化合物およびその用途 | |
| WO2008038251A3 (en) | 3-aza-bicyclo[3.1.0]hexane derivatives | |
| LT2225230T (lt) | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzoinės rūgšties kietos formos | |
| EP1854318A4 (en) | DYNAMIC IDENTITY ASSOCIATION IN A WIRELESS NETWORK | |
| MX2010004688A (es) | Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a. | |
| HUE026549T2 (hu) | 1-N-azacikloalkil-3-fenoxipropán pszichotróp gyógyszerek elõállítására alkalmas származékai | |
| AU2003269364A1 (en) | Use of piperazine derivatives as ccr1 antagonists | |
| SI2176229T1 (sl) | Nove kristalne oblike 3-(difluormetil)-1-metil-n-(3',4',5'-trifluor(1,1'-bifenil)-2-il)-1h- pirazol-4-karboksamida | |
| IL195355A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| WO2008033757A3 (en) | 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives | |
| AP2006003843A0 (en) | New heterocyclic carboxylic acid amide derivatives | |
| WO2008059519A3 (en) | A process for the preparation of intermediates of rosuvastatin | |
| WO2007062314A3 (en) | Heterocyclic cetp inhibitors | |
| HUP0500537A2 (en) | Process for the preparation of rosuvastatin via new intermediates | |
| ZA200801813B (en) | Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one | |
| AU2008339005A8 (en) | 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| ZA200705514B (en) | Preparation of pharmaceutical salts of piperazine compounds |